Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Murphy Canyon Acquisition Corp. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K/A Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur...
Docs: "SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MURPHY CANYON ACQUISITION CORP. September 21, 2023 Murphy Canyon Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware , DOES HEREBY CERTIFY AS FOLLOWS: 1. The present name of the Corporation is “Murphy Canyon Acquisition Corp”. The original certificate of incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on October 19, 2021 . The Corporation amended and restated the Original Certificate, which was filed with the Secretary of State of the State of Delaware on February 2, 2022 . 2. This Second Amended and Restated Certificate of Incorporation , which both restates and amends the provisions of the First Amended and Restated Certificate, was duly ...",
"AMENDED AND RESTATED BY LAWS OF CONDUIT PHARMACEUTICALS, INC. These Amended and Restated Bylaws of Conduit Pharmaceuticals, Inc. a Delaware corporation , are effective as of September 22, 2023, and hereby amend the restated bylaws of the Corporation in its entirety: ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either the principal place of business of the Corporation in the State of Delaware or the office of the corporation or individual acting as the Corporation’ s registered agent in Delaware.",
"INDEMNITY AGREEMENT is made and entered into as of __________, ______, between Conduit Pharmaceuticals Inc., a Delaware corporation , and ____________________ .",
"MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF CONDUIT PHARMACEUTICALS LIMITED",
"INDEX TO CONDENSED FINANCIAL STATEMENTS Unaudited Condensed Financial Statements of Conduit Pharmaceuticals Limited: Page Condensed Balance Sheets 2 Condensed Statements of Operations and Comprehensive Loss 3 Condensed Statements of Changes in Shareholders’ Deficit 4 Condensed Statements of Cash Flows 5 Notes to Condensed Financial Statements 6 1 CONDUIT PHARMACEUTICALS LIMITED BALANCE SHEETS",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION",
"Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination"
10/02/2023 SC 13G Nirland Ltd reports a 8.8% stake in Conduit Pharmaceuticals Inc.
09/29/2023 SC 13G St George Street Capital reports a 6.6% stake in CONDUIT PHARMACEUTICALS INC.
09/28/2023 8-K Quarterly results
08/23/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MURPHY CANYON ACQUISITION CORP. 4995 Murphy Canyon Road, Suite 300 San Diego, CA 92123 PROSPECTUS SUPPLEMENT SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON SEPTEMBER 7, 2023 To the Stockholders of Murphy Canyon Acquisition Corp.: This prospectus supplement amends and supplements the prospectus dated August 11, 2023 , which forms a part of the Registration Statement of Murphy Canyon Acquisition Corp. on Form S-4 . The Prospectus and Registration Statement relate to an offering of securities of MURF to shareholders of Conduit Pharmaceuticals Limited in connection with the proposed merger contemplated by that certain Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023 , which, among other things, provides for the merger of a wholly-own..."
08/23/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SEC Declares Form S-4 Registration Statement “Effective” for Proposed Business Combination of Murphy Canyon Acquisition Corp. with Conduit Pharmaceuticals Limited"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/08/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
07/28/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
07/21/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/21/2023 8-K Quarterly results
07/11/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
05/12/2023 S-4 Form S-4 - Registration of securities, business combinations:
05/11/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/11/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER"
04/14/2023 8-K Quarterly results
03/28/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A MMCAP International Inc. SPC reports a 2.5% stake in Murphy Canyon Acquisition Corp.
02/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2023 SC 13G Polar Asset Management Partners Inc. reports a 5% stake in MURPHY CANYON ACQUISITION CORP
02/03/2023 8-K Quarterly results
02/01/2023 8-K Quarterly results
01/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
01/30/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT TO AGREEMENT AND PLAN OF MERGER",
"FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED , AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. COMMON STOCK WARRANT",
"AMENDMENT TO SUBSCRIPTION AGREEMENT"
01/30/2023 SC 13D/A Murphy Canyon Acquisition Sponsor, LLC has filed a Schedule 13D for MURPHY CANYON ACQUISITION CORP.
01/03/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/08/2022 425 Form 425 - Prospectuses and communications, business combinations:
11/08/2022 8-K Investor presentation
Docs: "Conduit Pharmaceuticals to Become a Publicly Traded Company via Merger with Murphy Canyon Acquisition Corp."
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy